• 1 February 2017

    Will a focus on oncology bring blockbuster success?

    R&D costs associated with bringing a drug to market are stabilizing for large pharma; however, the industry is facing reduced returns on investments due to declining average peak-year sales from...

  • 30 January 2017

    The emergence of oncology biosimilars

    2017 will be a tumultuous one for the pharmaceutical industry as the major companies continue to struggle with the dreaded patent cliff - an extended period where a significant proportion...

  • 30 January 2017

    What does Brexit mean for medical regulation?

    On 17 January 2017, UK Prime Minister Theresa May outlined her vision for a hard Brexit, clarifying the government’s ambitions for a post-Brexit Britain. With the European Union (Notification of...

  • 30 January 2017

    Is ADHD an American Disorder?

    Attention-deficit/hyperactivity disorder (ADHD) is a common childhood disorder that can continue through adolescence and adulthood. Symptoms include higher than normal levels of impulsivity and inattention that prevent an individual from...

  • 27 January 2017

    CDK4/6 inhibitor rivalry in breast cancer begins

    Cyclin D kinase 4/6 (CDK4/6) inhibitors have shown great improvement in extending progression-free survival (PFS) in patients with human epidermal growth factor-negative (HER2-) and hormonal receptor positive (HR+) metastatic breast...


Go Top